跳至主要内容
临床试验/NCT01969370
NCT01969370已完成不适用

NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing

University of North Carolina, Chapel Hill2 个研究点 分布在 1 个国家目标入组 645 人开始时间: 2012年8月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
645
试验地点
2
主要终点
Extent of test-specific distress 2 weeks after return of results

研究概览

简要总结

This study is part of a larger consortium project investigating the validity and best use of next-generation sequencing (in particular, whole exome sequencing, or WES) in clinical care. This sub-project is investigating benefits and harms of providing WES diagnostic and different types of incidental findings to adult patients and parents of pediatric patients who undergo WES because they have symptoms suggesting genetic disease.

详细描述

This study is part of a larger consortium project investigating the validity and best use of next-generation sequencing (in particular, whole exome sequencing, or WES) in clinical care. Participants are patients who were either seen in the University of North Carolina Cancer and Adult Genetics Clinic or referred to the study by their physician. They will be approached by their physician or a genetic counselor for recruitment. Once enrolled, a clinical geneticist or genetic counselor will obtain consent and collect blood samples to be analyzed using WES. Results may include information related to a diagnosis and incidental information. Medically actionable incidental findings will be CLIA (Clinical Laboratory Improvement Amendments)-certified and returned to participants in a routine genetic counseling session, along with diagnostic findings. Eligible adult participants will be randomized to have the opportunity to choose to get certain types of non-medically actionable incidental findings, as well. Their decisions will be investigated, as will psychosocial and behavioral responses to sequencing and receiving sequencing information. This is a longitudinal, mixed methods study (i.e., multiple assessments pre- and post-return of results, with both quantitative and qualitative methods used to gather data). Because only the quantitative component of the study uses randomization, only measures and procedures associated with that component are described here.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Single (Outcomes Assessor)

入排标准

性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Extent of test-specific distress 2 weeks after return of results

时间窗: 2 weeks after return of diagnostic results; for adult patient participants who are eligible and who request them, 2 weeks after return of non-medically actionable incidental results

Measured with an adapted version of the multidimensional impact of testing scale (MICRA)

次要结局

  • Extent of information seeking(2 weeks after consent (T1) and change from T1 to 2 weeks after return of diagnostic results)
  • Extent of health-related Quality of Life 2 weeks after consent(All participants: 2 wks after consent (T1))
  • Extent of communication of test results with other people(2 weeks after return of diagnostic results)
  • Change in test-specific distress at 3 and 6 months after return of results(Adult patient participants: change from 2 weeks after return of diagnostic results to 3 months and 6 months after return of diagnostic results)
  • Extent of Decision Regret 2 weeks after consent(All participants: 2 wks after consent (T1))
  • Extent of Healthcare Utilization 2 weeks after return of results(All participants: 22 wks after return of diagnostic (dx) results)
  • Extent of Decision Regret 2 weeks after return of results(All participants: 2 wks after return of diagnostic (dx) results and, for eligible adults who request them, return of incidental results)
  • Change in decision regret(For all participants: Change from post-consent to post-return of results; Additional for adults: change at 3 and 6 months after return of dx results)
  • Extent of Healthcare Utilization 2 weeks after consent(All participants: 2 wks after consent (T1))
  • Change in Healthcare Utilization(All participants: Change in utilization from post-consent to post-return of results; Additional for adult patients: Change at 3 and 6 months after return of dx results)
  • Enactment of health-related lifestyle behaviors 2 weeks after consent(Adult participants: 2 wks after consent (T1))
  • Change in enactment of health-related lifestyle behaviors(Adult participants: Change in behaviors from 2 wks after consent (T1) to 2 wks, 3 months, and 6 months after return of dx results)
  • Change in extent of psychological distress(All participants: Change from 2 wks after consent (T1) to 2 wks after return of diagnostic (dx) results; Additional for adult patients: Change at 3 and 6 months after return of dx results)
  • Extent of health-related Quality of Life 2 weeks after return of results(All participants: 2 wks after return of diagnostic results)
  • Enactment of health-related lifestyle behaviors 2 weeks after return of results(Adult participants: 2 wks after return of diagnostic (dx) results)
  • Extent of psychological distress 2 weeks after consent(All participants: 2 wks after consent)
  • Extent of psychological distress 2 weeks after return of results(All participants: 2 wks after return of diagnostic (dx) results)
  • Change in extent of health-related Quality of Life(All participants: Change from 2 wks after consent to 2 weeks after return of diagnostic results)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

James Evans, MD, PhD

Clinical Professor

University of North Carolina, Chapel Hill

研究点 (2)

Loading locations...

相似试验

NCGENES: North Carolina Clinical Genomic Evaluation... | 临床试验